Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for Denali Therapeutics (DNLI) over the last 8 years, with Q3 2025 value amounting to $172.4 million.

  • Denali Therapeutics' Shares Outstanding (Diluted Average) rose 174.94% to $172.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $172.4 million, marking a year-over-year increase of 174.94%. This contributed to the annual value of $164.5 million for FY2024, which is 1972.97% up from last year.
  • Per Denali Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $172.4 million for Q3 2025, which was up 174.94% from $171.4 million recorded in Q2 2025.
  • Denali Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $172.4 million during Q3 2025, with a 5-year trough of $120.9 million in Q1 2021.
  • In the last 5 years, Denali Therapeutics' Shares Outstanding (Diluted Average) had a median value of $137.4 million in 2023 and averaged $142.1 million.
  • As far as peak fluctuations go, Denali Therapeutics' Shares Outstanding (Diluted Average) soared by 141.57% in 2022, and later surged by 2311.2% in 2024.
  • Quarter analysis of 5 years shows Denali Therapeutics' Shares Outstanding (Diluted Average) stood at $121.5 million in 2021, then rose by 3.3% to $125.5 million in 2022, then rose by 9.43% to $137.4 million in 2023, then grew by 19.73% to $164.5 million in 2024, then increased by 4.83% to $172.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $172.4 million in Q3 2025, compared to $171.4 million in Q2 2025 and $171.2 million in Q1 2025.